Dissecting the molecular profiling and tumor immune microenvironment of three subtypes of esophageal cancer

Great improvements have been made in the prognosis of esophageal cancer (ESCA) with the application of chemotherapy and immunotherapy. However, the majority of cases remain resistant to these regimens. Hence there is an urgent need to characterize the subtypes of ESCA with favorable survival outcome and drug responsiveness.

[1]  Kailin Xu,et al.  Immune Regulation of Poly Unsaturated Fatty Acids and Free Fatty Acid Receptor 4. , 2022, The Journal of nutritional biochemistry.

[2]  V. Buchholz,et al.  MYB orchestrates T cell exhaustion and response to checkpoint inhibition , 2022, Nature.

[3]  S. Tu,et al.  Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care , 2022, Cancers.

[4]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[5]  Min Yan,et al.  Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma , 2021, Frontiers in Immunology.

[6]  Z. Luo,et al.  [An optimized protocol of meniscus cell extraction for single-cell RNA sequencing]. , 2021, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[7]  D. Sahoo,et al.  FFAR4: A New Player in Cardiometabolic Disease? , 2021, Endocrinology.

[8]  Jing Wang,et al.  Decreased expression of Dlg5 is associated with a poor prognosis and epithelial–mesenchymal transition in squamous cell lung cancer , 2021, Journal of thoracic disease.

[9]  U. Schumacher,et al.  Infiltration of Immune Competent Cells into Primary Tumors and Their Surrounding Connective Tissues in Xenograft and Syngeneic Mouse Models , 2021, International journal of molecular sciences.

[10]  Lihua Zhang,et al.  Inference and analysis of cell-cell communication using CellChat , 2020, Nature Communications.

[11]  Angela N. Brooks,et al.  Visualizing and interpreting cancer genomics data via the Xena platform , 2020, Nature Biotechnology.

[12]  Linna Peng,et al.  Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis , 2020, Nature Communications.

[13]  L. Fu,et al.  The immune landscape of esophageal cancer , 2019, Cancer communications.

[14]  Jingting Jiang,et al.  Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer , 2019, Journal of experimental & clinical cancer research : CR.

[15]  Meijuan Huang,et al.  Upregulated FFAR4 correlates with the epithelial-mesenchymal transition and an unfavorable prognosis in human cholangiocarcinoma. , 2018, Cancer Biomarkers.

[16]  Juan Li,et al.  DLG5 suppresses breast cancer stem cell‐like characteristics to restore tamoxifen sensitivity by inhibiting TAZ expression , 2018, Journal of cellular and molecular medicine.

[17]  Christoph Hafemeister,et al.  Comprehensive integration of single cell data , 2018, bioRxiv.

[18]  Xia Li,et al.  TIP: A Web Server for Resolving Tumor Immunophenotype Profiling. , 2018, Cancer research.

[19]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[20]  Robert Damoiseaux,et al.  Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.

[21]  B. Hudson,et al.  Fatty acid 16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy resistance , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[23]  J. Qiu,et al.  Methylation-mediated silencing of Dlg5 facilitates bladder cancer metastasis. , 2015, Experimental cell research.

[24]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[25]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[26]  Juan Li,et al.  DLG5 in Cell Polarity Maintenance and Cancer Development , 2014, International journal of biological sciences.

[27]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[28]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[29]  Andrew E. Jaffe,et al.  Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .

[30]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[31]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  María José Domper Arnal,et al.  Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. , 2015, World journal of gastroenterology.

[33]  Peter D Siersema,et al.  Esophageal cancer. , 2008, Gastroenterology clinics of North America.

[34]  R. Truscott,et al.  Interferon-gamma-dependent/independent expression of indoleamine 2,3-dioxygenase. Studies with interferon-gamma-knockout mice. , 1999, Advances in experimental medicine and biology.

[35]  D. Gossot.  [Treatment of esophageal cancer]. , 1988, Soins. Chirurgie.